Project Grant R33CA281794
Award Date
8/1/24
Completion Date
7/31/27
Dollars Obligated
$416K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award of $231,413 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop a novel "SPINEX" (Separation-Processing Integration for Extracellular Vesicles) technology to streamline sample preparation for extracellular vesicle (EV) analysis. The project, awarded to The General Hospital Corporation (doing business as Massachusetts General Hospital), will create an automated,...
This $516,355.74 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, aims to develop new technologies for immunotherapy monitoring and liquid biopsy through the Cancer Research Manpower federal grant program. Specifically, the Massachusetts General Hospital will utilize the funding to create an ultra-high sensitive platform that can map single extracellular vesicles to parent cells at the single particle level and apply it to profile tumor...
This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop novel techniques to enrich cell-free DNA (cfDNA) and improve the sensitivity of circulating nucleic acid-based diagnostics. The $581,703 award, with a term from August 1, 2024 to May 31, 2028, will fund research at Massachusetts General Hospital (MGH)...
This Project Grant award of $427,095 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) will support the development of a novel microfluidic droplet-based platform (MDP) technology at Northeastern University. The goal is to generate and analyze a 3D biomimetic multicellular immunogenic tumor model that can: Establish multiple levels of hypoxia within a tumor-on-a-chip for parallel processing. Investigate the spatiotemporal interaction...
This federal Project Grant award for $576,716.86, awarded on September 12, 2024 by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), supports research and development of machine learning-enabled classification of extracellular vesicles (EVs) using nanoplasmonic microfluidics. The objective is to develop improved EV separation and SERS-based characterization techniques to enable more accurate diagnosis, classification, and monitoring of ovarian cancer. The project aims to...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The grant supports the development of a novel nanopore-based sequencing approach to accurately characterize repetitive DNA sequences, which are critical for understanding cancer progression but challenging to analyze using current sequencing-by-synthesis methods. The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) provides $419,133 to the Massachusetts Institute of Technology (MIT) for the "Advanced Development of Patient Ascites Therapeutic Response Biosensors" project. The goal is to develop the "AscitesPredict" technology, a label-free single-cell imaging and machine learning platform that can evaluate cell identities and therapeutic sensitivities from patient...
This Project Grant award, titled "DEVELOPING EXTRACELLULAR VESICLE-MEDIATED TARGETED MICRORNA DELIVERY SYSTEM FOR EGFR CANCERS," is funded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The $351,517 award to Michigan State University aims to establish a targeted therapeutic microRNA (miRNA) delivery system using engineered cell-derived extracellular vesicles (EVs) to target epidermal growth factor receptor (EGFR) cancers....
The Massachusetts General Hospital will receive $3,024,000 through a three-year Project Grant from the National Institutes of Health Trans-NIH Research Support program to develop scalable methods for engineering and characterizing novel CRISPR-associated protein variants. The goal is to address limitations of current CRISPR-Cas enzymes by optimizing machine learning-guided directed evolution to create a catalog of customizable DNA editors with improved properties like expanded target...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $298,999.00 to Numentus Technologies Inc. to develop a novel high-throughput, high-content imaging platform for the analysis of extracellular vesicles (EVs). The goal is to create a technology that can rapidly detect and characterize unique subpopulations of EVs, such as exosomes and outer membrane vesicles, at the...